Publication:
Myeloperoxidase and Advanced Oxidation Protein Products in the Cerebrospinal Fluid in Women and Men with Parkinson's Disease.

dc.contributor.authorFernandez-Espejo, Emilio
dc.contributor.authorRodriguez-de-Fonseca, Fernando
dc.contributor.authorGavito, Ana Luisa
dc.contributor.authorCordoba-Fernandez, Antonio
dc.contributor.authorChacon, Jose
dc.contributor.authorMartin-de-Pablos, Angel
dc.contributor.funderSociedad Andaluza de Neurología
dc.contributor.funderRETICS Red de Trastornos Adictivos
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderMinisterio de Ciencia e Innovación
dc.contributor.funderEuropean Regional Development Funds-European Union
dc.contributor.funderConsejería de Salud y Familia, Junta de Andalucía
dc.date.accessioned2023-05-03T13:46:53Z
dc.date.available2023-05-03T13:46:53Z
dc.date.issued2022-05-30
dc.description.abstractBackground: Myeloperoxidase (MPO) and advanced oxidation protein products, or AOPP (a type of MPO-derived chlorinated adducts), have been implicated in Parkinson´s disease (PD). Human MPO also show sex-based differences in PD. The objective was to study the relationship of MPO and AOPP in the cerebrospinal fluid (CSF) with motor features of idiopathic PD in male and female patients. Methods: MPO concentration and activity and AOPP content were measured in the CSF and serum in 34 patients and 30 controls. CSF leukocytes and the integrity of the blood-brain barrier were evaluated. Correlations of MPO and AOPP with clinical variables were examined. Results: The blood-brain barrier was intact and CSF leukocyte count was normal in all patients. CSF MPO concentration and activity were similar in the cohort of patients and controls, but CSF MPO content was significantly higher in male patients than in PD women (p = 0.0084). CSF MPO concentration correlated with disease duration in male and female patients (pCSF MPO concentration was significantly higher in men with a disease duration ≥12 years compared to the remainder of the male subjects (p < 0.01), while changes in CSF MPO in women were not significant. Serum MPO concentration and activity were significantly higher in all PD patients relative to controls (p < 0.0001), but CSF MPO was not correlated with serum MPO. Serum AOPP were detected in all patients, but CSF AOPP was undetectable in 53% of patients, with AOPP not being quantifiable in controls. The study concluded that CSF MPO is not a good biomarker for PD because mean CSF MPO concentration and activity do not differ between the cohort of patients and controls. While CSF MPO concentration positively correlated with disease duration in both men and women, it was only significantly enhanced in male patients with a disease duration longer than 12 years. This suggests that the MPO-related immune response may be weak in early-stage PD across all patients but progressively enhanced in men, not women. Given that the blood-brain barrier is intact and CSF MPO is not correlated with serum MPO, CSF myeloperoxidase likely reflects MPO content in brain cells rather than blood-derived cells. Finally, serum AOPP was detected in all patients but not controls, indicating the occurrence of chlorinative stress in blood serum in PD. The study of CSF AOPP as a biomarker could not be assessed due to the limitations of the ELISA assay in detecting it in the CSF.
dc.description.sponsorshipThis work was supported by grants to E.F.-E. from Sociedad Andaluza de Neurología (ref.SUBAIA2015/006), and RETICS Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISCIII, RD06/001/002); and to F.R.d.F. from Proyectos Retos Colaboración, Ministerio de Ciencia e Innovación and European Regional Development Funds-European Union (ERDF-EU, RTC2019-007329-1), EULAC-HEALTH H2020 FATZHEIMER Project (EULACH16/T010131), Red de Investigación en Atención Primaria en Adicciones, convocatoria RICORS 2021, ISCIII, Ministerio de Ciencia e Innovación and European Regional Development Funds-European Union (ERDF-EU; RD21/0009/0003); ISCIII and ERDF-EU (PI19/01577); and Consejería de Salud y Familia, Junta de Andalucía (NeuroRECA, RIC-0111-2019).
dc.description.versionSi
dc.identifier.citationFernández-Espejo E, Rodríguez de Fonseca F, Gavito AL, Córdoba-Fernández A, Chacón J, Martín de Pablos Á. Myeloperoxidase and Advanced Oxidation Protein Products in the Cerebrospinal Fluid in Women and Men with Parkinson's Disease. Antioxidants (Basel). 2022 May 30;11(6):1088
dc.identifier.doi10.3390/antiox11061088
dc.identifier.issn2076-3921
dc.identifier.pmcPMC9219636
dc.identifier.pmid35739985
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219636/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2076-3921/11/6/1088/pdf?version=1654140903
dc.identifier.urihttp://hdl.handle.net/10668/20783
dc.issue.number6
dc.journal.titleAntioxidants (Basel, Switzerland)
dc.journal.titleabbreviationAntioxidants (Basel)
dc.language.isoen
dc.organizationHospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.organizationHospital Universitario Virgen Macarena
dc.page.number14
dc.provenanceRealizada la curación de contenido 21/02/2025
dc.publisherMDPI
dc.pubmedtypeJournal Article
dc.relation.projectIDSUBAIA2015/006
dc.relation.projectIDRD06/001/002
dc.relation.projectIDRTC2019-007329-1
dc.relation.projectIDEULACH16/T010131
dc.relation.projectIDRD21/0009/0003
dc.relation.projectIDPI19/01577
dc.relation.publisherversionhttps://www.mdpi.com/resolver?pii=antiox11061088
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectParkinson’s disease
dc.subjectAdvanced oxidation protein products
dc.subjectCerebrospinal fluid
dc.subjectDuration
dc.subjectMyeloperoxidase
dc.subject.decsProductos avanzados de oxidación de proteínas
dc.subject.decsSuero
dc.subject.decsBarrera hematoencefálica
dc.subject.decsPeroxidasa
dc.subject.decsBiomarcadores
dc.subject.decsLeucocitos
dc.subject.meshBlood-Brain Barrier
dc.subject.meshAdvanced Oxidation Protein Products
dc.subject.meshSerum
dc.subject.meshParkinson Disease
dc.subject.meshBrain
dc.subject.meshPeroxidase
dc.subject.meshBiomarkers
dc.titleMyeloperoxidase and Advanced Oxidation Protein Products in the Cerebrospinal Fluid in Women and Men with Parkinson's Disease.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number11
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9219636.pdf
Size:
1006.17 KB
Format:
Adobe Portable Document Format